Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Taiyo to Expand "Total Contract Manufacturing" Business
March 8, 2004
- BUSINESS NEWS IN BRIEF
March 8, 2004
- PFSB to Revise GL on Information Disclosure
March 8, 2004
- REGULATORY NEWS IN BRIEF
March 8, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 8, 2004
- Chuikyo Approves FY2004 Medical Fee Revision Proposal
March 1, 2004
- OTC NEWS IN BRIEF
March 1, 2004
- REGULATORY NEWS IN BRIEF
March 1, 2004
- MEDICAL DEVICE NEWS IN BRIEF
March 1, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 1, 2004
- DIAGNOSTIC NEWS IN BRIEF
March 1, 2004
- JT Sees Pharma Business as "Next-generation Mainstay"
March 1, 2004
- Wishing to Keep AGR of 10-15% for Coming Years: Dr Tallarigo of Eli Lilly
March 1, 2004
- Sales of Daiichi's Coversyl Beginning to Slacken
March 1, 2004
- Heparinized Saline Kit Market Growing Rapidly
March 1, 2004
- BUSINESS NEWS IN BRIEF
March 1, 2004
- WEBSITE NEWS
March 1, 2004
- Chugai Aims at Top in Priority Fields: Cancer, Nephropathy, Bone
March 1, 2004
- Taisho: Downward Revisions in FY2003 Business Forecast
March 1, 2004
- 1st 3 Qtrs Business Results
March 1, 2004
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…